<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01535677</url>
  </required_header>
  <id_info>
    <org_study_id>D1691C00007</org_study_id>
    <nct_id>NCT01535677</nct_id>
  </id_info>
  <brief_title>To Compare the Similarity of a Combination Dapagliflozin/Metformin Tablet With the Two Drugs Administered Separately</brief_title>
  <official_title>A Bioequivalence Study of the Fixed Dose Combination Dapagliflozin/Metformin Tablet (5 mg/850 mg) Relative to a 5 mg Dapagliflozin Tablet and an 850 mg Metformin (Glucophage® Marketed in Canada by Sanofi-Aventis) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This is an open-label, randomised study to compare the similarity of a combination
      Dapagliflozin/Metformin tablet with the two drugs administered separately under fasting and
      fed conditions in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Bioequivalence Study of the Fixed Dose Combination Dapagliflozin/Metformin Tablet (5.0
      mg/850 mg) Relative to a 5.0 mg Dapagliflozin Tablet and an 850 mg Metformin (Glucophage®
      Marketed in Canada by Sanofi-Aventis) Tablet Co-Administered to Healthy Subjects in the
      Fasted and Fed States
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve over the time (AUC)</measure>
    <time_frame>pre-dose, 0.25 min, 0.5 min, 1h, 1.5h, 2 h, 3h , 4 h, 5 h , 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h, 60 h and 72 h post-dose</time_frame>
    <description>No statistical analysis will be performed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time zero to the time of last quantifiable analyte concentration (AUC(0-t))</measure>
    <time_frame>pre-dose, 0.25 min, 0.5 min, 1h, 1.5h, 2 h, 3h , 4 h, 5 h , 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h, 60 h and 72 h post-dose</time_frame>
    <description>No statistical analysis will be performed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>pre-dose, 0.25 min, 0.5 min, 1h, 1.5h, 2 h, 3h , 4 h, 5 h , 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h, 60 h and 72 h post-dose</time_frame>
    <description>No statistical analysis will be performed</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum analyte concentration (tmax)</measure>
    <time_frame>pre-dose, 0.25 min, 0.5 min, 1h, 1.5h, 2 h, 3h , 4 h, 5 h , 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h, 60 h and 72 h post-dose</time_frame>
    <description>No statistical analysis will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal rate constant (λz)</measure>
    <time_frame>pre-dose, 0.25 min, 0.5 min, 1h, 1.5h, 2 h, 3h , 4 h, 5 h , 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h, 60 h and 72 h post-dose</time_frame>
    <description>No statistical analysis will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of last quantifiable analyte concentration (tlast)</measure>
    <time_frame>pre-dose, 0.25 min, 0.5 min, 1h, 1.5h, 2 h, 3h , 4 h, 5 h , 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h, 60 h and 72 h post-dose</time_frame>
    <description>No statistical analysis will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>pre-dose, 0.25 min, 0.5 min, 1h, 1.5h, 2 h, 3h , 4 h, 5 h , 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h, 60 h and 72 h post-dose</time_frame>
    <description>No statistical analysis will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed maximum analyte concentration (Cmax)</measure>
    <time_frame>pre-dose, 0.25 min, 0.5 min, 1h, 1.5h, 2 h, 3h , 4 h, 5 h , 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h, 60 h and 72 h post-dose</time_frame>
    <description>No statistical analysis will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC)</measure>
    <time_frame>pre-dose, 0.25 min, 0.5 min, 1h, 1.5h, 2 h, 3h , 4 h, 5 h , 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h, 60 h and 72 h post-dose</time_frame>
    <description>No statistical analysis will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-curve from time zero to the time of last quantifiable analyte concentration (AUC(0 t))</measure>
    <time_frame>pre-dose, 0.25 min, 0.5 min, 1h, 1.5h, 2 h, 3h , 4 h, 5 h , 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h, 60 h and 72 h post-dose</time_frame>
    <description>No statistical analysis will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination terminal half-life (t1/2)</measure>
    <time_frame>pre-dose, 0.25 min, 0.5 min, 1h, 1.5h, 2 h, 3h , 4 h, 5 h , 6 h, 8 h, 10 h, 12 h, 16 h, 24 h, 30 h, 36 h, 42 h, 48 h, 54 h, 60 h and 72 h post-dose</time_frame>
    <description>No statistical analysis will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile description in term of Adverse Events</measure>
    <time_frame>from first dose in treatment period 1 up to 10 days after final dose</time_frame>
    <description>No statistical analysis will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile description in term of Blood Pressure</measure>
    <time_frame>at screening, once daily during the residential period (5 days each) and up to 10 days after final dose</time_frame>
    <description>No statistical analysis will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile description in term of Physical Examination</measure>
    <time_frame>at screening, Day -1 and Day 4 at Visits 2 to 5 and up to 10 days after final dose</time_frame>
    <description>No statistical analysis will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile description in term of Electrocardiogram ECG</measure>
    <time_frame>at screening and up to 10 days after final dose</time_frame>
    <description>No statistical analysis will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile description in term of Heart Rate</measure>
    <time_frame>at screening, once daily during the residential period (5 days each) and up to 10 days after final dose</time_frame>
    <description>No statistical analysis will be performed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile description in term of Safety Labs</measure>
    <time_frame>at screening, on Day -1 and Day 4 (72 hours post-dose) at Visits 2 to 5 and up to 10 days after final dose</time_frame>
    <description>No statistical analysis will be performed</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg dapagliflozin and 850 mg Glucophage in fasted state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dapagliflozin/metformin (5 mg/850 mg) immediate release (IR) FDC in fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg dapagliflozin and 850 mg Glucophage in fed state</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dapagliflozin/metformin (5 mg/850 mg) IR FDC in fed state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin + Glucophage tablet fasted</intervention_name>
    <description>Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fasted state</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin/metformin IR FDC tablet fasted</intervention_name>
    <description>single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fasted state</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin + Glucophage tablet fed</intervention_name>
    <description>Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fed state</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin/metformin IR FDC tablet fed</intervention_name>
    <description>single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fed state</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers aged 18 to 55 years inclusive with suitable veins for cannulation
             or repeated vein puncture

          -  Male subjects should be willing to use barrier contraception ie, condoms and
             spermicide, from the day of dosing until at least 3 months after dosing with the
             investigational product

          -  Non-pregnant, non-lactating female subjects who if pre-menopausal are using adequate
             birth control eg, oral, injectable, transdermal or implanted hormonal contraceptives,
             vaginal contraceptive ring, intrauterine device (IUD)/intrauterine systems

          -  Have a body mass index (BMI) between 18.5 and 30.0 kg/m2 inclusive (ie, within 15% of
             normal range) and weigh at least 50 kg and no more than 100 kg.

        Exclusion Criteria:

          -  History or presence of gastrointestinal, hepatic or renal disease or any other
             condition known to interfere with absorption, distribution, metabolism or excretion of
             drugs

          -  Any clinically important abnormalities in rhythm, conduction or morphology of resting
             ECG that may interfere with individual safety evaluation Current smokers who smoke
             more than 5 cigarettes per day (or equivalent use of tobacco products) or cannot give
             up smoking during the study

          -  Excessive intake of caffeine containing drinks eg, coffee, tea, caffeine containing
             energy drinks and cola (more than 5 cups of coffee or equivalent per day)

          -  Plasma donation within one month of screening or any blood donation/blood loss &gt;500 mL
             during the 3 months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva Johnsson, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Research and Development SE-431 83 Mölndal Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Saeed Kahn, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Drug Research Unit at Guy's Hospital, 6 Newcomen St, London SE1 1YR</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mirjana Kujacic, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca Research and DevelopmentSE-431 83 Mölndal Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1195&amp;filename=D1691C00007_CSR_Synopsis.pdf</url>
    <description>D1691C00007_CSR_Synopsis</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1195&amp;filename=D1691C00007_Clinical_Study_Protocol_Redacted.pdf</url>
    <description>D1691C00007_Clinical_Study_Protocol</description>
  </link>
  <results_reference>
    <citation>Chang M, Liu X, Cui D, Liang D, LaCreta F, Griffen SC, Lubin S, Quamina-Edghill D, Boulton DW. Bioequivalence, Food Effect, and Steady-State Assessment of Dapagliflozin/Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects. Clin Ther. 2015 Jul 1;37(7):1517-28. doi: 10.1016/j.clinthera.2015.05.004. Epub 2015 Jun 3.</citation>
    <PMID>26048185</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>February 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2012</study_first_posted>
  <last_update_submitted>July 8, 2015</last_update_submitted>
  <last_update_submitted_qc>July 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>cross-over study</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Bioequivalence</keyword>
  <keyword>Cmax</keyword>
  <keyword>tmax</keyword>
  <keyword>AUC</keyword>
  <keyword>AUC(0-t)</keyword>
  <keyword>λz</keyword>
  <keyword>tlast</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

